Oncimmune Share Discussion Threads

[tole] 13/2/2020 19:29

Im tempted now after the clearing trade. Did look at it after the update too and thought it read well. Plenty of upside from here.

[waterloo01] 13/2/2020 16:08

Finally some buyers. Been awhile.

[smackeraim] 13/2/2020 15:57

Just me watching this then?

Ticking up on every few grand bought now.

[smackeraim] 13/2/2020 14:37

Shares not in Public HandsIn accordance with the definition in the AIM Rules for Companies and insofar as it is aware, as at 31st October 2019, 39.5% of the Company's AIM securities was not in public hands.

[smackeraim] 13/2/2020 14:25

Next month!Completion of the strategic commercialisation agreement with Biodesix, Inc. for EarlyCDT Lung in the United States with Biodesix commercial launch expected in early March (Q1) 2020; the agreement is valued at up to $28m over the initial 5 year period.

[smackeraim] 13/2/2020 14:10

Very large trades. Cleared seller? All good!

[zho] 12/2/2020 17:49

I clicked on this thread by mistake but it rang a bell about something I'd read recently:

[waterloo01] 12/2/2020 07:29

Revenues up (but still relatively marginal) but with significant cost savings and £7m cash, post loan) they should have a couple of years cash, so cash call not an issue this year. If they can see the US market (launching this month) ramp up and get anywhere with the NHS and NICE then this should do well.

Seems cheap given the prospects.

[shearluc] 28/1/2020 11:14

Agreed, Hopefully a reputable angency demonstrating cost-effectiveness will make some of the NHS accountant types take more notice.
If this takes off in China where Ca lung is an even bigger problem then this share will really fly!

[waterloo01] 28/1/2020 08:27

Very under loved and under the radar share.

[waterloo01] 27/1/2020 18:54

A study funded by The National Institute for Health Research (NIHR) SBRI programme and led by Leeds University Academic Unit of Health Economics, supported by the NIHR Leeds In-vitro Diagnostics Co-operative (NIHR Leeds MIC), shows that using a blood test in the cancer risk assessment of indeterminate pulmonary nodules is highly cost-effective and could speed the time to diagnosis.

At a price point of £70, a blood test known as the EarlyCDT Lung test is more effective compared to CT surveillance with an incremental cost-effectiveness ratio (ICER) of less than £2,500 depending on the test accuracy parameters used.

Lung cancer is one of the most prevalent forms of cancer and kills more women than breast and ovarian cancers combined. Five-year survival rates for breast and bowel cancer patients are 86% and 59% respectively. Both of these cancers have screening programmes. Five-year survival for lung cancer, which has no screening programme, is less than 10%.

Oncimmune’s Early-CDT Lung is a simple ELISA blood test that measures seven lung cancer-specific antibodies and can be used for the assessment of malignancy risk in patients with indeterminate pulmonary nodules (IPNs).

Robust and easy to use, it can be run in any laboratory with standard laboratory equipment and more than 160,000 tests have been sold. A ‘kit’ form of the test was CE marked in May 2017 for distribution to laboratories outside the USA.

Dr Helen Radford, Director of Operations, NIHR Leeds MIC, said: “This exciting and important project also included an NHS laboratory validation alongside focus groups with members of the public to understand the patient's perception in early lung cancer screening and how this blood test could help. We look forward to working with Oncimmune in the future.”

Dr Adam M. Hill, CEO, Oncimmune Plc said: “The NIHR Leeds MIC was an excellent delivery partner for this project. Their support in bringing the multidisciplinary teams together from across the University and local NHS Trust enabled us to generate further data in support of our adoption discussions with the NHS.”

[waterloo01] 12/12/2019 07:52

Oncimmune
@OncimmuneECDT
·
30m
We are so delighted to receive the #BioNewsRoundAward at #Genesis19. Incredibly proud of the Oncimmune team, the ECLS team for their support and most of all, our ECLS trial heroes who helped tell the story of the true impact EarlyCDT Lung can have on early #lungcancer detection.

[waterloo01] 01/11/2019 07:43

and only RNS'd today?

[waterloo01] 25/10/2019 14:59

I've been adding a few. Results next week. They sold the US site as part of the US deal for $1m and have said costs would reduce by about $2.2m. Having got some bank debt recently of £5.5m they say are cashed into 2021.

Some of the deals should also start to kick in, although that will probably be slow to build but hopefully it will mark a turnaround in the share price

[waterloo01] 11/9/2019 07:21

New blood test trialled on 12,000 Scots catches lung cancer early

Chief investigator, Prof Frank Sullivan, said the findings could have "globally significant implications".

Experts hope the test will now be rolled out across Scotland and beyond.

[waterloo01] 03/9/2019 12:11

Looking forward to the update on the Scottish trial

[pugugly] 28/6/2019 07:54

Sounds like good news but how much have they had to give away to get it? Initial MM mark-up

[waterloo01] 04/6/2019 08:09

Looking good. Quite some trial that's ongoing

[waterloo01] 21/5/2019 09:22

Up 80% on launch of lung cancer test. Under the radar here!

Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer